[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607558":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":32,"collaborators":10,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":10,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":48,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Hasan Kalyoncu University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Hemophilia A Group",null,"This will be the first assessment before the child begins treatment with emicizumab. During the first month of treatment, the child and parents will be asked to note any joint or muscle bleeding, including the bleeding site, duration of bleeding, and whether hospitalization is necessary. At the end of the first month, parents will be contacted by phone to assess bleeding episodes, and any bleeding that occurred during the first month will be recorded. The same assessments will then be repeated at the third and sixth months of treatment. The effectiveness of the treatment will be assessed after the first six months through an analysis of the assessments.",[13],{"name":14,"affiliation":5,"role":15},"Tuğba GÖNEN, Asisst. Prof. Dr.","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","505 090 58 46","tugba.badat@hku.edu.tr",[22],{"facility":5,"status":10,"city":23,"state":23,"zip":24,"country":25,"countryCode":10,"cosmosGeoPoint":26,"geoPoint":31,"contacts":10},"Gaziantep","(505) 090-5846","Turkey (Türkiye)",{"type":27,"coordinates":28},"Point",[29,30],37.3825,37.05944,{"lat":30,"lon":29},{"type":15,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Tuğba GÖNEN","Asisst. Prof. Dr.","100607558","effects-of-emicizumab-treatment-in-patients-with-hemophilia-a-100607558",false,"NCT07190118","Effects of Emicizumab Treatment in Patients With Hemophilia A","Effects of Emicizumab Treatment on the Musculoskeletal System in Children With Hemophilia A: A Prospective Study","Inclusion Criteria:\n\n* Children who are under 18 years of age,\n* Have been diagnosed with Hemophilia A by a physician,\n* Have a factor level of 1% (IU) or less,\n* Have inhibitors positive or negative,\n* Have no obstacles to starting subcutaneous (emicizumab) treatment,\n* Willing to participate in the study\n\nExclusion Criteria:\n\n\\- Children with a history of cerebrovascular bleeding who present any neurological findings that would prevent participation in the study","MALE","1 Year","18 Years",{"count":46,"type":47},20,"ESTIMATED","6 Months","OBSERVATIONAL","The aim of our study is to investigate the effects of emicizumab treatment on the musculoskeletal system in children with hemophilia A.",[52,53,54],"Hemophilia A","Musculoskeletal Assessment","Musculoskeletal Abnormalities",[52,56,57,58],"Emicizumab","Musculoskeletal system","Measurement","NOT_YET_RECRUITING","2025-09-23",{"date":62,"type":63},"2025-09-24","ACTUAL",{"date":65,"type":47},"2025-09-30",{"date":67,"type":47},"2026-02-10",{"name":5,"class":6},1]